Head and Neck Carcinoma Clinical Trial
Official title:
A Digital Intervention Protocol to Enhance Recovery After Head and Neck Surgery
Verified date | October 2022 |
Source | OHSU Knight Cancer Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This trial studies examines the impact of virtual reality (VR) experiences and Fitbit wearable activity devices on postoperative recovery after head and neck surgery. Virtual reality has shown to help rehabilitation and pain control primarily in non-surgical fields, and researchers are interested in using this to help postoperative pain control. Early mobilization after surgery is also important, and may increase lung capacity, improve gastrointestinal function, reduce pain, and reduce risk of deep venous thrombosis. Use of virtual reality and Fitbit devices may improve postoperative pain control and reduce narcotic use among hospitalized patients after head and neck surgery.
Status | Completed |
Enrollment | 80 |
Est. completion date | October 6, 2022 |
Est. primary completion date | October 6, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 89 Years |
Eligibility | Inclusion Criteria: - English speaking (Ability to interact with virtual reality content may be impacted by inability to understand English) - Older than 18 years of age and younger than 89 years of age. Both men and women and members of all races and ethnic groups will be included - Planned to undergo major surgery at Oregon Health & Science University (OHSU) with the Department of Otolaryngology-Head and Neck Surgery with an expected length of stay (LOS) of 2 days or more - Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: - Planned postoperative admission to the intensive care unit (ICU) - Social or psychiatric conditions that may interfere with compliance - Isolation precautions - Complex head and neck procedure requiring resection or reconstruction involving the scalp, orbit, or mid-face. This would limit the ability to utilize the VR headset - Reconstruction, incisions, wounds, wound care, or injury that impact the ability to place on the VR headset or wear a Fitbit device around the wrist. This would limit the ability to utilize the VR headset or the Fitbit device - History of seizure or epilepsy - History of vertigo or persistent dizziness - Use of cardiac pacemaker, requirement for hearing aid on at all times, or have defibrillators - Limitations that impair mobility. This would limit the ability to utilize the Fitbit device - Use of a walker or wheelchair at baseline. This would limit the ability to utilize the Fitbit device - Children - Pregnant women - Neonates of uncertain viability or nonviable neonates - Decisionally impaired adults - Prisoners |
Country | Name | City | State |
---|---|---|---|
United States | OHSU Knight Cancer Institute | Portland | Oregon |
Lead Sponsor | Collaborator |
---|---|
OHSU Knight Cancer Institute | Oregon Health and Science University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Pain scores | Will review the electronic medical record (EMR) to evaluate daily pain scores among patients, and average these scores to obtain the daily pain score. May also look at differences between AM and PM pain scores among the different cohorts. Additionally, we plan to evaluate pain scores obtained pre and post-VR use. Descriptive statistics can be used to present the results of anxiety. One-way ANOVA and two-sample t-test can be used to compare differences between the groups. | Through study completion (pre and post-VR use), an average of 10 days | |
Other | Anxiety | Will use the Generalized Anxiety Disorder 7-Item scale to determine preoperative and postoperative level of anxiety. Scores may represent mild (6-10), moderate (11-15), and severe (16-21) anxiety. Descriptive statistics can be used to present the results of anxiety. One-way ANOVA and two-sample t-test can be used to compare differences between the groups. | Before surgery and at study completion, an average of 10 days | |
Other | Depression | Will use the Patient Health Questionaire-9 to determine preoperative and postoperative level of depression. This is a screening instrument with 9 items that measures depression, with answers as not at all, several days, more than half of the days, and nearly every day (score 0-27). Scores may represent mild (5-9), moderate (10-19), and severe (>= 20) depression. Descriptive statistics can be used to present the results of depression. One-way ANOVA and two-sample t-test can be used to compare differences between the groups. | Before surgery and at study completion, an average of 10 days | |
Other | Sleep quality | Will use the Insomnia Severity Index to determine preoperative and postoperative sleep quality. Items are rated on a 5-point Likert scale, and a total score ranges from 0 to 28. Scores may represent subthreshold (8-14), moderate (15-21), or severe (22-28) insomnia. Descriptive statistics can be used to present the results of sleep quality. One-way ANOVA and two-sample t-test can be used to compare differences between the groups. | Before surgery and at study completion, an average of 10 days | |
Other | Sleep patterns | Will evaluate sleep patterns among patients with Fitbit devices to better understand inpatient sleep in the hospital. Descriptive statistics can be used to present the results of LOS. One-way and two-sample t-test can be used to analyze differences between the groups. | At study completion, an average of 10 days | |
Other | Hospital satisfaction | Will use a Visual Analogue Scale to analyze patient satisfaction during hospitalization, and which would be provided to patients on day of discharge. The Visual Analogue Scale (VAS) is a horizontal line that is 100-mm long, with no satisfaction (0) on the very left and extreme satisfaction on the very right (100). Descriptive statistics can be used to present the results of hospital satisfaction. One-way ANOVA and two-sample t-test can be used to compare differences between the groups. | At study completion, an average of 10 days | |
Other | Disposition on discharge | Will evaluate data regarding disposition on discharge to home, home with home health, skilled nursing facility, inpatient rehabilitation facility, remain in hospital, other facility, or remaining in the hospital from the EMR on the day of discharge or day 14 of hospital stay. Descriptive statistics can be used to present the results of disposition on discharge. Chi-square test can be used to compare differences between the groups. | At study completion, an average of 10 days | |
Other | Length of stay (LOS) | Will determine LOS beginning from postoperative day one and to include the day of discharge. Descriptive statistics can be used to present the results of LOS. One-way ANOVA and two-sample t-test can be used to analyze differences between the groups. | At study completion, an average of 10 days | |
Primary | Mean daily opioid use | Will be assessed using milligram morphine equivalents (MME). Narcotic use may be compared using One-Way Analysis of Variance (ANOVA) and two sample t-test can be used to compare the narcotic use between intervention group and control group (virtual reality [VR]+Fitbit versus [vs.] control, VR vs. control, Fitbit vs. control). Furthermore, a linear regression model including demographic and clinical characteristic variables with a P-value =< 0.1 will be used to determine factors associated with reduced narcotic use. | Through study completion, an average of 10 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04110249 -
Photoacoustic Imaging for Measuring Tumors and Normal Tissue in Patients With Head and Neck Cancer
|
N/A | |
Not yet recruiting |
NCT06289049 -
Heavy Strength Training in Head and Neck Cancer Survivors
|
Phase 2 | |
Completed |
NCT01831089 -
Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT03663985 -
FALCOn (Facteur AnthropoLogique Cancer Orl)
|
||
Recruiting |
NCT05544136 -
A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer
|
Phase 2 | |
Recruiting |
NCT05077072 -
Interdisciplinary Interventions to Address Pain Management Among Head and Neck Cancer Patients
|
Phase 2 | |
Recruiting |
NCT04151082 -
High Dose Steroid Therapy (Prednisone or Methylprednisolone) for the Improvement of Symptoms of Late Radiation-Associated Lower Cranial Neuropathy in Oropharyngeal Cancer Survivors
|
Phase 1/Phase 2 | |
Completed |
NCT03964896 -
Nurse-Driven Telephone Intervention in Improving Side Effects in Cancer Patients Undergoing Chemotherapy
|
N/A | |
Recruiting |
NCT04147494 -
Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues
|
Early Phase 1 | |
Completed |
NCT02474095 -
Acupuncture-Like Transcutaneous Electrical Nerve Stimulation in Treating Radiation-Induced Xerostomia in Patients With Head and Neck Cancer
|
N/A | |
Withdrawn |
NCT03261180 -
Nestle Impact Advanced Recovery in Improving Surgery Recovery in Patients With Head and Neck Cancer
|
N/A | |
Terminated |
NCT04618432 -
Collection of Clinical Data and Specimens for Research on Head and Neck and Communication Disorders
|
||
Active, not recruiting |
NCT02615275 -
Bioelectrical Impedance Analysis in Estimating Body Composition in Patients With Stage I-IV Head and Neck Cancer Undergoing Radiation Therapy
|
N/A | |
Terminated |
NCT05012397 -
Milademetan in Advanced/Metastatic Solid Tumors
|
Phase 2 | |
Recruiting |
NCT00991094 -
Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy
|
||
Recruiting |
NCT04870762 -
Customized 3D Printed Oral Stents During Head and Neck Radiotherapy
|
Phase 2 | |
Completed |
NCT02369835 -
Modified Dakin's Solution in Reducing Radiation-Induced Dermatitis in Patients With Head and Neck Cancer Undergoing Radiation Therapy
|
Phase 3 | |
Completed |
NCT03902535 -
Geriatric and Quality of Life Assessments in Older Patients With Non-metastatic or Metastatic Head and Neck or Lung Cancer Undergoing Surgery or Chemoradiation and Their Caregivers
|
||
Recruiting |
NCT05526924 -
Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
|
Phase 1 | |
Recruiting |
NCT03795610 -
Window of Opportunity Study of IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma
|
Phase 2 |